| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The molecular targets include serotonin 5-HT2 receptors, α1-adrenergic receptors, histamine H1 receptors, and muscarinic acetylcholine receptors, where cyclobenzaprine acts as an antagonist; its muscle-relaxant effect is mediated centrally through 5-HT2 receptor antagonism and α1-adrenergic blockade, while H1 and muscarinic antagonism contribute to sedation and anticholinergic side effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, cyclobenzaprine-d6 HCl competes with radioligands for 5-HT2, α1, H1, and muscarinic receptors with nanomolar to low-micromolar affinity, and it antagonizes serotonin- and phenylephrine-induced signaling in transfected cells; the deuterated form retains receptor antagonist activity while enabling LC-MS/MS quantification. |
| ln Vivo |
In vivo, oral cyclobenzaprine-d6 HCl reduces skeletal muscle tone and spasticity in rodent models, increases the latency to flexion reflex, and produces sedation through central H1 and 5-HT2 blockade; the labeled form is used to quantify plasma and brain concentrations and to relate multi-receptor occupancy to muscle-relaxant and sedative effects.
|
| Enzyme Assay |
Noncellular binding assays incubate membrane homogenates expressing recombinant 5-HT2A, α1A, H1, or muscarinic M1 receptors with selective radioligands and increasing concentrations of cyclobenzaprine-d6 HCl; Ki values are calculated from displacement curves, and selectivity across the receptor panel is determined.
|
| Cell Assay |
Cellular functional assays use CHO or HEK293 cells expressing 5-HT2A or α1A receptors and measure cyclobenzaprine-d6 HCl–mediated antagonism of agonist-induced calcium mobilization or inositol phosphate accumulation; H1 and muscarinic antagonism are assessed in parallel, with functional potency expressed as IC50.
|
| Animal Protocol |
Animal protocols administer cyclobenzaprine-d6 HCl orally or intraperitoneally to rats or mice at doses of 1–30 mg/kg; muscle tone by electromyography, flexor reflex latency, and locomotor activity are measured, and plasma and brain concentrations are quantified by LC-MS/MS to relate receptor occupancy to muscle-relaxant and sedative effects.
|
| References |
|
| Molecular Formula |
C20H16D6CLN
|
|---|---|
| Molecular Weight |
317.89
|
| Exact Mass |
317.182
|
| CAS # |
2748492-38-6
|
| Related CAS # |
Cyclobenzaprine hydrochloride;6202-23-9
|
| PubChem CID |
163322547
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
3.2
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
365
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N(CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31)C([2H])([2H])[2H].Cl
|
| InChi Key |
VXEAYBOGHINOKW-TXHXQZCNSA-N
|
| InChi Code |
InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H/i1D3,2D3;
|
| Chemical Name |
3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)-N,N-bis(trideuteriomethyl)propan-1-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1457 mL | 15.7287 mL | 31.4574 mL | |
| 5 mM | 0.6291 mL | 3.1457 mL | 6.2915 mL | |
| 10 mM | 0.3146 mL | 1.5729 mL | 3.1457 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.